2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

801. Gene Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Chimeric Antigen Receptor, Gene Therapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Hemophilia, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Autoimmune Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Pediatric, Animal Model
PAPER

2545 Retrospective study of motixafortide stem cell mobilization for exagamglogene autotemcel gene therapy in sickle cell disease

Stephan A Grupp, MD, PhD, Pooja Khandelwal, MD2, Jaap Jan Boelens, MD, PhD3, Roberta C. G. Azbell, MD4, Hemalatha Geetharani Rangarajan I, MD5, Kris Mahadeo, MD6, John P Manis, MD7, Robert Nickel, MD, MSc8, Christopher McKinney, MD9, Timothee Sourdille, MD10, Aric Parnes, MD11, Keith Davis, MA12, Lizzi Esterberg, MS13, Rabi Hanna, MD14
1 Children's Hospital of Philadelphia, Philadelphia, United States
2 Cincinnati Children’s Hospital Medical Center, Cincinnati, United States
3 Memorial Sloan Kettering Cancer Center, New York, United States
4 The Ohio State University/The James Comprehensive Cancer Center, Columbus, United States
5 Nationwide Children's Hospital, Columbus, United States
6 Duke University, Durham, United States
7 Boston Children's Hospital, Boston, United States
8 Children's National Hospital, Washington, United States
9 Children's Hospital Colorado, Aurora, United States
10 Vertex Pharmaceuticals Incorporated, Boston, United States
11 Vertex Pharmaceuticals Incorporated, Boston, United States
12 RTI Health Solutions, Durham, United States
13 RTI Health Solutions, Durham, United States
14 Cleveland Clinic, Cleveland, United States

Background: Hematopoietic stem cell (HSC)-based gene therapy for sickle cell disease (SCD) requires mobilization and collection of adequate HSCs; however, current mobilization approaches are limited, as G-CSF is contraindicated and plerixafor, while standard of care can yield suboptimal and inconsistent collections requiring repeated procedures. This results in substantial patient burden that delays receipt of gene therapy. Motixafortide is increasingly used for HSC mobilization in SCD, but evidence remains limited.

Methods: In this retrospective, multicenter study in the US, we evaluated the safety, HSC mobilization, collection and manufacturing outcomes of patients with SCD who received motixafortide from Jan 2024-May 2026 for exagamglogene autotemcel (exa-cel) manufacturing, an autologous CRISPR-Cas9 gene editing therapy. Safety endpoints were assessed across all motixafortide cycles. Peak peripheral blood (PB) CD34+ counts and total CD34+ collection yields were evaluated for all motixafortide cycles and prior or subsequent plerixafor cycles. Exa-cel manufacturing outcomes included the drug product (DP) yield ratio between motixafortide- and plerixafor-mobilized cycles.

Results: The study included 35 patients from 10 US centers. Mean ± SD age at first motixafortide mobilization was 23.5 ± 6.8 years, with 22.9% (n=8) aged <18 years. Most patients were Black/African American (90.9%; n=30) and 51.4% (n=18) were male. HbSS was the predominant genotype (88.6%, n=31), followed by HbS/β-thalassemia (n=3) and HbSD (n=1). Among patients with available vaso-occlusive crisis (VOC) history (n=34), all had experienced at least one event, with a mean ± SD annualized rate of 7.3 ± 7.0 events prior to the first motixafortide cycle. A total of 107 mobilization cycles were captured: 51 motixafortide and 56 plerixafor cycles. Most patients (80.0%; n=28) received a prior plerixafor mobilization cycle before their first motixafortide mobilization. Among 49 motixafortide cycles with available dosing data, 19 (38.8%) were categorized as single-dose motixafortide, 24 (49.0%) as a two-dose regimen (daily dose for a 2-day collection cycle), and 6 (12.2%) as other multi-dose regimens.

The most common adverse events across 51 motixafortide cycles were injection-site reactions/local pain (78.4%; n=40) and pruritus (58.8%; n=30), followed by VOC (21.6%; n=11) and urticaria (19.6%; n=10). One anaphylactic event was reported and resolved rapidly after treatment. Rates of injection-site reactions/local pain and pruritus were generally comparable between single-dose and two-dose regimens. Prophylactic regimens were used in nearly all cycles, most commonly H2 blockers (98.0%), leukotriene inhibitors (95.9%), and H1 antihistamines (93.9%); motixafortide-related complications were most often managed with antihistamines (52.9%), analgesics (47.1%), and corticosteroids (33.3%).

Mean ± SD peak PB CD34+ counts were 142.0 ± 84.8 cells/µL across motixafortide cycles and 57.6 ± 39.0 cells/µL across plerixafor cycles. Mean ± SD total CD34+ collection yields per cycle were 12.8 ± 8.5 ×10⁶ cells/kg across motixafortide cycles and 8.6 ± 5.0 ×10⁶ cells/kg across plerixafor cycles. Among motixafortide cycles, the two-dose regimen was associated with higher peak PB CD34+ counts (163.4 ± 99.6 vs 128.0 ± 69.6 cells/µL) and total CD34+ collection yields (13.9 ± 8.7 vs 11.6 ± 9.2 ×10⁶ cells/kg) than the single-dose regimen, with the largest differences observed between regimens on the second collection day for both PB CD34+ counts (134.6 ± 102.7 vs 66.0 ± 51.9 cells/µL) and collection yields (6.8 ± 4.2 vs 2.7 ± 1.8 ×10⁶ cells/kg). The mean drug product yield following motixafortide mobilization was 2.35-fold higher than following plerixafor mobilization, reflecting the higher CD34+ collection yields achieved with motixafortide, while individual manufacturing step performance remained similar between mobilization groups.

Conclusions: In this retrospective, multicenter cohort of 35 patients with SCD undergoing HSC mobilization for exa-cel manufacturing, many with prior poor mobilization, motixafortide was associated with higher CD34+ mobilization and collection yields compared with plerixafor in the largest motixafortide study in SCD to date. Injection-site reactions/local pain and pruritus were the most commonly reported adverse events. These data suggest motixafortide may enhance HSC mobilization and improve cell collection for exa-cel manufacturing in patients with SCD.

Stephan A Grupp, MD, PhD: Vertex - Research Funding; Kite - Research Funding; Servier - Research Funding; Cellectis - Research Funding; Novartis - Research Funding; Novartis - Consultancy (Includes expert testimony); Vertex - Consultancy (Includes expert testimony); Estrella - Consultancy (Includes expert testimony); Adaptive Biotech - Consultancy (Includes expert testimony)